moneyheap
RVMD · Analysis updated Nov 11, 2026, 4:47 PM ET
Why is Revolution Medicines, Inc. (RVMD) stock moving?
Revolution Medicines is in its first quarter as a commercial-stage company. RASONQUE brought in $197.6M in about five weeks, against analyst expectations of $50M-$100M. It has treated more than 5,000 patients, and insurers covering over 90% of patients are reimbursing claims. Analysts responded with higher price targets, such as HC Wainwright at $350, and the rating mix is heavily Buy. The shares are still volatile. On Nov 5 they fell to $177.65 on about 7.8M shares, versus roughly 1-2M on a normal day. They rebounded to $200.15 on Nov 9, then slid to $193.06 on Nov 10. Today they trade near $180.70 on about 3.3M shares so far, which is below the recent range. Management said early sales include initial channel stocking and patients moving over from expanded access, and it is too early to call the launch trajectory. Q3 net loss was $407M. Insiders sold about $59M of stock over 90 days. Upcoming items include the EU decision after the positive CHMP opinion and ongoing NSCLC trials. The strong launch is likely already reflected in a roughly $39B-$43B valuation, and the stock is in a choppy pullback.
News behind the analysis
- Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressRASONQUE net product revenue was $197.6M for the quarter, covering about five weeks of sales after the U.S. launch.
- Revolution's Rasonque off to best cancer drug launch 'in history'Sales of $198M beat analyst expectations of $50M-$100M. Executives said it is too early to draw conclusions about the launch trajectory.
- Rasonque, Revolution Medicines' pancreatic cancer drug, sees big launchMore than 5,000 patients were treated in five weeks. Sales were nearly double even the most bullish estimates.
- Revolution Medicines at Guggenheim Healthcare Innovation Conference: launch gainsManagement described a strong early launch. It also warned that first-wave sales may not reflect the longer-term run rate.
- Revolution Medicines' Anthony Mancini: 'We're just getting started' as Rasonque nears EU approvalThe company is launching without a partner. The CHMP has recommended EU authorization for previously treated metastatic pancreatic cancer.
- Revolution Medicines (RVMD) Rallies On RASONQUE Launch As Fair Value Debate Heats UpQ3 revenue was $197.56M with a net loss of $407.46M. The shares rose 8.24% in one day, but the 30-day and 90-day returns are negative.
- Research Analysts Set Expectations for RVMD FY2026 EarningsHC Wainwright holds a Buy rating and a $350 target. Insiders sold 290,991 shares worth about $59.4M over 90 days.
- Revolution Medicines (RVMD) Launches RASONQUE, Surpasses $198M in Initial U.S. SalesThe drug generated $198M in net revenue within five weeks of launch and has treated more than 5,000 patients.
About Revolution Medicines, Inc. Common Stock
Revolution Medicines is a Redwood City, California biotech that develops cancer drugs aimed at RAS, a family of proteins that are mutated in many hard-to-treat tumors, such as pancreatic, lung and colorectal cancer. It now calls itself a commercial-stage company: its lead RAS(ON) inhibitor, daraxonrasib (RMC-6236), is sold as RASONQUE for previously treated metastatic pancreatic cancer, and RMC-9805 and RMC-6291 are among the drugs still in its pipeline.
How it makes money
For most of its history the company had no approved products. It brought in little revenue, mostly from collaboration deals, and paid for its research through stock sales and partnership funding. It is now moving toward revenue from selling RASONQUE, but it is still deeply unprofitable, with net losses of roughly $1.8 billion over the past year, so its research and launch spending is far larger than its income.
What usually moves RVMD
- Clinical trial data for RAS(ON) inhibitors
- Regulatory decisions in the US and Europe
- Early RASONQUE launch sales
- Competition from other RAS-targeted drugs
- Cash runway and stock offerings